AGP Picks
View all

Antibody production market to hit $53.78B by 2030

Oct. 30, 2026
Antibody production market to hit $53.78B by 2030
By AI, Created 13:15 UTC, Oct 30, 2026, AGP -

The antibody production market is growing quickly as drugmakers, biotech firms and research labs expand demand for monoclonal antibodies and related manufacturing services. The market is projected to rise from $25.89 billion in 2025 to $30.02 billion in 2026, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Antibody production underpins therapies and diagnostics used for cancer, autoimmune disease, diabetes and other chronic conditions. - Faster market growth signals more investment in biologics manufacturing, contract production and advanced bioprocessing capacity. - Rising demand for research-grade antibodies and scalable manufacturing is reshaping competition across pharmaceutical and biotech supply chains.

What happened: - The Business Research Company released a new antibody production market analysis covering global demand patterns and the competitive landscape. - The report estimates the market will grow from $25.89 billion in 2025 to $30.02 billion in 2026. - The report projects the market will reach $53.78 billion by 2030. - The report says the market is expanding at a 16.0% CAGR in 2026 and a 15.7% CAGR over the forecast period. - The analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Market growth is being driven by broader pharmaceutical and biotech research, higher use of monoclonal antibodies and growth in CRO and CDMO services. - The report points to increased investment in biologics manufacturing as a key support for future demand. - The forecast also cites expanding therapeutic antibody pipelines and a shift toward continuous bioprocessing. - The report highlights growing interest in cost-effective production methods. - Trends include wider use of recombinant antibody production, demand for high-yield expression systems and more automation in upstream and downstream processing. - Contract antibody manufacturing is gaining share as buyers seek scalability and reproducibility. - Antibody production includes in vivo and in vitro methods designed to generate antibodies for research, diagnostic and therapeutic use. - Antibodies bind specifically to antigens and are used to support targeted therapies and precise diagnostics. - Chronic disease prevalence is a major demand driver because long-term conditions often require ongoing monitoring and treatment. - The NHS reported in June 2024 that 3,615,330 people in the UK were diagnosed with non-diabetic hyperglycemia in 2023, up 18% from 3,065,825 in 2022.

Between the lines: - North America held the largest market share in 2025 because of established pharmaceutical infrastructure and high healthcare spending. - Asia-Pacific is expected to be the fastest-growing region as biopharmaceutical activity and healthcare investment rise. - The report’s emphasis on automation and reproducibility suggests buyers are prioritizing manufacturing efficiency over pure capacity growth. - The inclusion of market attractiveness scoring, TAM analysis, company scoring matrices and Excel dashboards shows the report is aimed at strategy teams tracking where to compete.

What's next: - The market is expected to keep expanding as biologics pipelines move forward and more production shifts to contract manufacturers. - Continuous bioprocessing and recombinant production techniques are likely to gain broader adoption. - Manufacturers that can deliver lower-cost, higher-yield and more scalable output are positioned to benefit most. - Regional growth in Asia-Pacific may intensify competitive pressure on established North American and European suppliers.

The bottom line: - Antibody production is moving from a fast-growing niche into a core biomanufacturing market, with demand driven by chronic disease, biologics pipelines and outsourcing.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Business Post Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Business Post Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.